Flex Pharma, Inc. (FLKS)
(Delayed Data from NSDQ)
$0.46 USD
-0.02 (-3.26%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.46 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Salarius Pharmaceuticals, Inc. [FLKS]
Reports for Purchase
Showing records 1 - 20 ( 85 total )
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ValuEngine Detailed Valuation Report for FLKS
Provider: ValuEngine, Inc
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Dropping Coverage
Provider: H.C. Wainwright & Co., Inc.
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Signals Lend Support to FLX-787?s Utility in Multiple Sclerosis Spasticity
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MS Data Suggests New Value Opportunity; Reiterate Buy and $12 PT
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Upcoming Data Should Mark Official Transition of FLKS to a Pharma Company; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
New Year, New Flex; Resuming with Buy and $12 PT
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are placing shares of FLKS Under Review, and transferring coverage to Jotin Marango, M.D., Ph.D.
Provider: Roth Capital Partners, Inc.
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Small Trial, But Strong Efficacy Signals from FLX-787 in ALS
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Small Trial, But Strong Efficacy Signals from FLX-787 in ALS
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M